Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria for Tumor Collection:~1. Diagnosis or clinical signs of advanced RCC~2. Scheduled for cytoreductive or partial nephrectomy~Key Exclusion Criteria for Tumor Collection:~1. Known inability to undergo sunitinib treatment as currently labeled, due to pre-existing medical conditions~2. Requirement for systemic chronic immunosuppressive drugs or corticosteroids~3. Evidence of brain metastases prior to nephrectomy~Key Inclusion Criteria for Treatment Study:~1. Advanced disease, histologically assessed as RCC, with predominantly clear cell histology~2. Metastatic disease (measurable or non-measurable) that can be monitored throughout the course of the study participation per RECIST 1.1~3. Subjects who are candidates for standard first-line therapy initiating with sunitinib~4. Time from diagnosis to treatment \< 1 year~5. Karnofsky performance status (KPS) ≥ 70%~6. Life expectancy of 6 months or greater~7. Resolution of all acute toxic effects of prior radiotherapy or surgical procedures to Grade ≤ 1 according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0~8. Adequate hematologic, renal, hepatic, and coagulation function~9. Negative serum pregnancy test for female subjects with reproductive potential, and agreement of all male and female subjects of reproductive potential to use a reliable form of contraception during the study and for 12 weeks after the last dose of study drug~10. Normal ECG or clinically non-significant finding(s) at Screening~11. Able to abstain from taking prohibited drugs, either prescription or non-prescription, during the treatment phase of the study~12. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures~Key Exclusion Criteria for Treatment Study:~1. Prior systemic therapy (including adjuvant or neoadjuvant) of any kind for RCC, including immunotherapy, chemotherapy, hormonal, or investigational therapy~2. Prior history of malignancy within the preceding 3 years, except for adequately treated in situ carcinomas or non-melanoma skin cancer, adequately treated early stage breast cancer, superficial bladder cancer, and non-metastatic prostate cancer with a normal PSA~3. History of or known brain metastases, spinal cord compression, or carcinomatous meningitis, or evidence of brain or leptomeningeal disease~4. Patients with 4 or more of the following risk factors:~   1. Hgb \< LLN~  2. Corrected calcium \> 10.0 mg/dL~  3. KPS \< 80%~  4. Neutrophils \> ULN~  5. Platelets \> ULN~5. Planned or elective surgical treatment post-nephrectomy for the direct management of RCC, within 28 days before Visit 1 (Week 0)~6. NCI CTCAE Grade 3 hemorrhage \< 28 days before Visit 1 (Day 0)~7. Clinically significant cardiovascular conditions within 3 months prior to Randomization~8. Significant gastrointestinal abnormalities~9. Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication~10. Active autoimmune disease or condition requiring chronic immunosuppressive therapy~11. Clinically significant infections, including human immunodeficiency virus, syphilis, and active hepatitis B or C~12. Current treatment with an investigational therapy on another clinical trial~13. Pregnancy or breastfeeding~14. Any serious medical condition or illness considered by the investigator to constitute an unwarranted high risk for investigational treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AGS-003 + Standard Treatment (Type: EXPERIMENTAL): Subjects on this arm will receive standard treatment for Renal Cell Carcinoma. In addition, subjects will receive AGS-003.
- Standard Treatment (Type: ACTIVE_COMPARATOR): Subjects on this arm will receive standard treatment for Renal Cell Carcinoma.

Based on this trial design, predict the completion outcome and termination type (if applicable).